Codexis, Inc. CDXS
At closeNov 5, 2026, 4:08 PM EST
After hours · Nov 5, 4:08 PM ET
- YTD
- -37.42%
- 1 year
- -52.56%
- Market cap
- 111.70M
- Revenue (ttm)
- 64.45M
- Profit margin
- -96.35%
- EPS (ttm)
- -0.33
- Shares out
- 81.38M
- Forward P/E
- -7.14
- YTD return
- -37.42%
- 1-year return
- -52.56%
- Volume
- 870.79K
- Avg volume
- 936.33K
- Open
- 1.09
- Previous close
- 1.08
- Day's range
- 0.9919 – 1.10
- 52-week range
- 0.96 – 2.98
- Beta
- 2.07
- Price target
- 7.17 (+602.6%)
5D -0.19 (-15.70%)
Key statistics
- Enterprise value
- 381.27M
- PEG ratio
- 0.00
- Price / sales
- 6.23
- Price / book
- 5.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 38.30%
- Free cash flow
- -8.12M
- Total cash
- 90.25M
- Total debt
- 41.85M
- Return on equity
- -75.31%
- Short % of float
- 2.36%
- 50-day average
- 4.19
- 200-day average
- 3.43
Analyst view
- Target (low)
- 3.00
- Target (mean)
- 7.17
- Target (high)
- 11.00
- Strong buy1
- Buy4
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.02167.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.25 | -0.29 | -0.04 | -16.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.26 | -0.32 | -0.06 | -23.08% |
| May 2, 2024 | Mar 1, 2024 | -0.17 | -0.16 | +0.01 | +5.88% |
| Feb 28, 2024 | Dec 1, 2023 | -0.16 | 0.02 | +0.18 | +112.50% |
| Nov 2, 2023 | Sep 1, 2023 | -0.32 | -0.26 | +0.06 | +18.75% |
| Aug 3, 2023 | Jun 1, 2023 | -0.21 | -0.17 | +0.04 | +19.05% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 22, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 15, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 4, 2024 | Benchmark | reit | — | Hold |
| Sep 20, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 29, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 19, 2024 | Benchmark | down | Buy | Hold |
About Codexis, Inc.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- codexis.com
News
Codexis to Report Third Quarter 2026 Financial Results on November 12 
Codexis Enters Agreement With An Unnamed siRNA Drug Innovator To Explore Stereo-Defined Fragment Synthesis Using Its ECO Synthesis Manufacturing Platform 
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA 
Reviewing Codexis (NASDAQ:CDXS) & Revvity (NYSE:RVTY) 
Analyzing Codexis (NASDAQ:CDXS) and Mettler-Toledo International (NYSE:MTD) 
BlackRock Inc. Makes New Investment in Codexis, Inc. $CDXS 
Codexis to Participate in Cantor Global Healthcare Conference 2026 
Piper Sandler Maintains Overweight on Codexis, Lowers Price Target to $8 
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? 
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on CDXS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DE VRE RAYMOND | Director | Stock Award(Grant) | Nov 6, 2024 | 47,846 |
| DORGAN BYRON L | Director | Stock Award(Grant) | Jun 10, 2024 | 223,581 |
| ERBEZ GEORGIA L | Chief Financial Officer | Stock Award(Grant) | Oct 9, 2024 | 50,000 |
| MARTINBOROUGH ESTHER | Director | Stock Award(Grant) | Jun 10, 2024 | 88,053 |
| MOORE ALISON | Chief Technology Officer | Stock Award(Grant) | Oct 9, 2024 | 148,696 |
| OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 24, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Opaleye Management Inc. | 10.78% | 8,770,000 | 43.24M | Sep 29, 2024 |
| Casdin Capital, LLC | 9.95% | 8,100,000 | 39.93M | Sep 29, 2024 |
| Blackrock Inc. | 8.50% | 6,915,734 | 34.09M | Sep 29, 2024 |
| FMR, LLC | 5.53% | 4,497,090 | 22.17M | Sep 29, 2024 |
| Vanguard Group Inc | 5.10% | 4,152,719 | 20.47M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 3.65% | 2,967,808 | 14.63M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.55% | 2,075,798 | 10.23M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.23% | 1,811,668 | 8.93M | Oct 30, 2024 |
| Columbia Fds Ser Tr I-Columbia Small Cap Value Fd I | 1.56% | 1,267,085 | 6.25M | Jul 30, 2024 |
| Variable Insurance Products Fund-Growth Portfolio | 1.40% | 1,141,000 | 5.63M | Oct 30, 2024 |
| Fidelity Advisor Equity Growth Fund | 1.38% | 1,122,880 | 5.54M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.25% | 1,016,202 | 5.01M | Sep 29, 2024 |